MeiraGTx AAV-hAQP1 Gene Therapy Shows Durable 3-Year Phase 1 Benefit for Radiation-Induced Xerostomia
MeiraGTx announced positive 3-year Phase 1 AQUAx data for AAV-hAQP1, a gene therapy delivering the aquaporin-1 water channel protein via Stensen's duct to the parotid glands of head-and-neck cancer survivors with grade 2/3 radiation-induced dry mouth. Clinically meaningful XQ symptom improvements and unstimulated salivary flow increases were maintained through 3 years. BLA submission planned H1 2027.